Company (Location)

Product

Description

Indication

Status (Date)#

Elevation Pharmaceuticals Inc. (San Diego)

EP-101

An inhalation solution formulation of long-acting muscarinic antagonist glycopyrrolate delived by eFlow Nebulizer System

Chronic obstructive pulmonary disease

Phase IIa data showed it demonstrated a statistically significant and well-tolerated improvement in lung function over 24 hours compared to placebo (9/27)

InterMune Inc. (Brisbane, Calif.)

Esbriet

Pirfenidone

Idiopathic pulmonary fibrosis

Data supported the longer-term safety and tolerability of Esbriet (9/27)

Mundipharma International Inc. (Cambridge, UK)

Flutiform

A combination of fluticasone propionate, an inhaled corticosteroid and long-acting beta2-agnist formoterol fumarate

Asthma

Phase III data showed it improved lung function and effectively controlled symptoms across different asthma severities in adolescents and adults (9/27)

Pearl Therapeutics Inc. (Redwood City, Calif.)

PT003

Dual bronchodilator combination product

Chronic obstructive pulmonary disease

Phase IIb data demonstrated that PT003 provided superior inspiratory capacity compared to Spiriva HandiHaler (9/27)

Notes:

Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue.

# The date indicated refers to the BioWorld Today issue in which the news item can be found.